TY - JOUR
T1 - Effect of high-dose posaconazole on serum levels in adult patients with hematologic malignancy
AU - DiPippo, Adam J.
AU - McDaneld, Patrick M.
AU - Tverdek, Frank P.
AU - Kontoyiannis, Dimitrios P.
N1 - Funding Information:
D.P.K. reports research support from Gilead, Inc., and Astellas, Inc., and honoraria from Merck & Co, Astellas Pharma, Gilead Sciences, and Cidara Therapeutics. A.J.D., P.M.M., and F.P.T. have no conflicts of interest to disclose.
Publisher Copyright:
Copyright © 2021 American Society for Microbiology. All Rights Reserved.
PY - 2021/12
Y1 - 2021/12
N2 - Posaconazole (POS) appears to have dose-proportional pharmacokinetics; however, there is a paucity of real-life data. We retrospectively evaluated 67 patients with hematologic cancer who had POS dose increases from 300 mg/day to either 400 mg/day (n = 52) or 300 mg twice daily (BID) (n = 15) and for whom POS serum levels were measured. Median POS levels were 840 ng/ml, 1,625 ng/ml, and 2,710 ng/ml for the dosages of 300 mg/day, 400 mg/day, and 300 mg BID, respectively. Significant interpatient variability in serum levels was noted.
AB - Posaconazole (POS) appears to have dose-proportional pharmacokinetics; however, there is a paucity of real-life data. We retrospectively evaluated 67 patients with hematologic cancer who had POS dose increases from 300 mg/day to either 400 mg/day (n = 52) or 300 mg twice daily (BID) (n = 15) and for whom POS serum levels were measured. Median POS levels were 840 ng/ml, 1,625 ng/ml, and 2,710 ng/ml for the dosages of 300 mg/day, 400 mg/day, and 300 mg BID, respectively. Significant interpatient variability in serum levels was noted.
KW - Fungal infection
KW - Posaconazole
KW - Serum levels
KW - Therapeutic drug monitoring
UR - http://www.scopus.com/inward/record.url?scp=85119323344&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119323344&partnerID=8YFLogxK
U2 - 10.1128/AAC.01230-21
DO - 10.1128/AAC.01230-21
M3 - Article
C2 - 34570643
AN - SCOPUS:85119323344
SN - 0066-4804
VL - 65
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 12
M1 - e01230-21
ER -